What Is CJC-1295 No DAC?
CJC-1295 No DAC is a synthetic peptide based on growth hormone-releasing hormone, or GHRH.
GHRH is naturally produced by the hypothalamus and signals the pituitary gland to release growth hormone.
The peptide commonly called CJC-1295 No DAC is more accurately described as Modified GRF 1-29, a modified version of the active 29-amino-acid portion of GHRH.
The modifications are intended to make the peptide more resistant to rapid enzymatic breakdown while preserving its ability to stimulate growth hormone release.
This gives it a relatively short-acting profile that is designed to work with the body’s natural pulsatile growth hormone system.
Why Are Researchers Interested in It?
Growth hormone is released naturally in pulses rather than at a constant rate.
Those pulses are influenced by sleep, age, exercise, nutrition, and several other hormones.
Researchers are interested in CJC-1295 No DAC because it does not simply supply growth hormone from outside the body. Instead, it acts upstream by signaling the pituitary gland to release more of the body’s own GH.
That creates a very different research model from direct HGH administration.
The main areas of interest include growth hormone secretion, IGF-1 signaling, body composition, recovery, sleep, metabolic function, tissue repair, and age-related changes in the GH axis.
How Does CJC-1295 No DAC Work?
CJC-1295 No DAC binds to GHRH receptors on cells in the anterior pituitary.
Activation of these receptors stimulates the release of growth hormone.
Growth hormone then acts directly on tissues and also stimulates production of insulin-like growth factor 1, or IGF-1, particularly in the liver.
The result is activation of the broader GH/IGF-1 axis.
Because Modified GRF 1-29 is relatively short acting, its effects are generally discussed in the context of pulsatile stimulation rather than prolonged continuous exposure.
That distinction is one of the main reasons it has attracted interest in peptide research.
Why “No DAC” Matters
The “DAC” in CJC-1295 refers to Drug Affinity Complex.
The original long-acting CJC-1295 molecule was designed with a DAC modification that allows it to bind to albumin and remain active much longer in circulation.
CJC-1295 No DAC does not contain that long-acting modification.
As a result, it behaves much more like a short-acting GHRH analogue.
This is why CJC-1295 No DAC and long-acting CJC-1295 with DAC should not be treated as interchangeable compounds.
Their duration of action and resulting hormone-release patterns are quite different.
CJC-1295 No DAC vs. Modified GRF 1-29
In peptide markets, these names are often used interchangeably.
Technically, Modified GRF 1-29 is the more accurate name for the short-acting peptide commonly sold as CJC-1295 No DAC.
The confusion comes from the popularity of the CJC name.
True CJC-1295 was originally developed as a longer-acting GHRH analogue with the DAC modification.
The “No DAC” version lacks that defining component.
For research purposes, this naming distinction matters because studies involving long-acting CJC-1295 cannot automatically be assumed to apply directly to Modified GRF 1-29.
Growth Hormone Release
The strongest scientific rationale for Modified GRF 1-29 is straightforward: it is designed to stimulate pituitary growth hormone release.
Natural GHRH already performs this role in human physiology.
Modified GRF 1-29 preserves the biologically active portion of GHRH while incorporating changes intended to improve stability.
The result is a compound designed to produce a temporary increase in GH secretion while still relying on the body’s own pituitary gland.
This makes it particularly useful for investigating how enhanced physiological GH pulses affect downstream biology.
IGF-1 Research
Growth hormone and IGF-1 are closely connected.
GH stimulates the liver and other tissues to produce IGF-1, which participates in growth, tissue remodeling, protein synthesis, and metabolic signaling.
Because CJC-1295 No DAC increases GH release, researchers are also interested in its downstream effects on IGF-1.
The magnitude of this effect can depend on dose, timing, pituitary responsiveness, age, nutrition, and whether the peptide is combined with another growth hormone secretagogue.
The GH/IGF-1 relationship is one of the main reasons this peptide is discussed in research involving recovery and body composition.
CJC-1295 No DAC + Ipamorelin
One of the most common research combinations pairs Modified GRF 1-29 with ipamorelin.
These two peptides stimulate growth hormone through different receptor systems.
CJC-1295 No DAC acts through the GHRH receptor.
Ipamorelin acts through the ghrelin receptor, also known as the growth hormone secretagogue receptor.
Because the pathways are different but complementary, researchers are interested in whether stimulating both at the same time can create a stronger GH pulse than either signal alone.
This combination has become especially popular in peptide research involving recovery, sleep, body composition, and age-related GH decline.
Why Combine GHRH and a Secretagogue?
Normal growth hormone release is controlled by several interacting signals.
GHRH encourages GH release.
Somatostatin suppresses it.
Ghrelin and related signals can also stimulate it.
Using both a GHRH analogue and a ghrelin-receptor agonist gives researchers a way to activate two separate stimulatory pathways at once.
From a physiological standpoint, this is an elegant concept.
Rather than replacing GH directly, the approach attempts to amplify the body’s own signaling machinery.
Body Composition Research
Growth hormone has important effects on body composition.
It influences fat metabolism, protein turnover, and lean tissue.
This is why CJC-1295 No DAC is frequently discussed in research involving body fat, muscle preservation, recovery, and metabolic health.
The peptide itself should not be described as a proven fat-loss or muscle-building treatment.
However, its ability to stimulate GH gives researchers a clear biological reason to examine these outcomes.
The most important question is how much intermittent GH stimulation through GHRH pathways changes body composition over time.
Fat Metabolism
Growth hormone has well-established lipolytic effects.
Lipolysis is the breakdown of stored fat into fatty acids that can be used for energy.
Because CJC-1295 No DAC stimulates GH release, researchers are interested in whether this can influence fat mobilization and body-fat regulation.
This pathway is one reason GH-releasing peptides are frequently discussed in metabolic and body-composition research.
The effect is indirect: the peptide stimulates GH, and GH then influences adipose-tissue metabolism.
Recovery & Tissue Research
The GH/IGF-1 axis plays a major role in tissue growth, repair, and adaptation.
Researchers therefore have an interest in CJC-1295 No DAC in relation to exercise recovery, musculoskeletal repair, connective tissue, and general tissue remodeling.
Growth hormone signaling can affect protein synthesis, collagen turnover, and cellular recovery.
This provides a biological rationale for studying GHRH analogues in recovery-related settings.
How strongly these effects translate into measurable clinical improvements with Modified GRF 1-29 specifically remains an area that needs more direct research.
Sleep & Nighttime GH Pulses
One of the largest natural growth hormone pulses occurs during deep sleep.
This relationship between sleep and GH is one reason GHRH-related peptides are frequently discussed in nighttime research protocols.
GHRH signaling also has connections with sleep physiology beyond simply releasing GH.
Researchers have studied GHRH pathways in relation to slow-wave sleep and sleep architecture.
This makes sleep an interesting area for Modified GRF 1-29 research, especially because the peptide’s short duration may allow researchers to study pulse timing more precisely.
Aging & Growth Hormone
Growth hormone secretion generally declines with age.
This age-related decline is sometimes referred to as somatopause.
Researchers have studied how reduced GH and IGF-1 signaling may relate to changes in body composition, muscle mass, recovery, sleep, and metabolic function.
GHRH analogues are therefore of interest because they attempt to stimulate the existing endocrine system rather than replacing GH directly.
The question is whether restoring stronger physiological pulses can reproduce some benefits associated with a younger GH pattern while avoiding problems associated with excessive hormone exposure.
CJC-1295 No DAC vs. HGH
CJC-1295 No DAC and human growth hormone operate at different points in the same endocrine system.
HGH supplies the hormone directly.
CJC-1295 No DAC signals the pituitary gland to release endogenous GH.
That means the peptide still depends on pituitary capacity and natural endocrine feedback.
This can create a more physiological pattern of hormone release.
Researchers are interested in whether this type of stimulation offers advantages compared with continuous or externally supplied GH.
Evidence Snapshot
Mechanistic evidence: Strong. GHRH receptor biology and pituitary growth hormone release are well established.
Parent-pathway evidence: Strong. GHRH has been extensively studied in human physiology.
Modified GRF research: Scientifically plausible but less extensive than research on the broader GHRH pathway.
Growth hormone effects: Well established downstream. GH has known effects on metabolism, tissue remodeling, and IGF-1 production.
Combination research: Biologically compelling. Pairing a GHRH analogue with a ghrelin-receptor agonist creates a strong mechanistic rationale for enhanced pulsatile GH release.
Direct long-term clinical evidence for CJC-1295 No DAC: Limited compared with established endocrine therapies.
What Do We Know?
The basic biology behind CJC-1295 No DAC is very well established.
GHRH signals the pituitary gland to release growth hormone.
Growth hormone then influences IGF-1, fat metabolism, tissue repair, protein turnover, and numerous other biological processes.
Modified GRF 1-29 was designed to improve upon natural GHRH’s very short lifespan while preserving this signaling function.
That gives the peptide a solid physiological foundation.
Its appeal comes from the fact that it works with the endocrine system rather than replacing growth hormone outright.
What Are Researchers Still Trying to Determine?
Researchers still need more direct long-term human data specifically evaluating Modified GRF 1-29.
Important questions include optimal timing, dose-response relationships, changes in GH pulse amplitude, effects on IGF-1, body composition, sleep, metabolic health, and long-term safety.
Researchers are also interested in how outcomes differ when the peptide is used alone versus paired with compounds such as ipamorelin.
Another important question is whether intermittent peptide-driven GH stimulation produces different biological effects from continuous elevation of GH or IGF-1.
Research & Regulatory Status
CJC-1295 No DAC / Modified GRF 1-29 is not an FDA-approved medication in the United States.
It remains an experimental research peptide.
Its biological target, however, is not mysterious.
The GHRH receptor and the GH/IGF-1 axis are among the better-characterized endocrine systems in human physiology.
This gives Modified GRF 1-29 a stronger mechanistic foundation than many experimental compounds, even though direct clinical evidence for the specific peptide remains more limited.
Your Pep Resource Takeaway
CJC-1295 No DAC is one of the more logically designed peptides in growth-hormone research.
It builds directly on the body’s natural GHRH system and is designed to stimulate endogenous, pulsatile growth hormone release.
That makes it fundamentally different from simply supplying HGH.
Its strongest scientific foundation comes from decades of research into GHRH, growth hormone, IGF-1, and the endocrine pathways controlling GH pulses.
Interest becomes even greater when Modified GRF 1-29 is paired with a ghrelin-receptor agonist such as ipamorelin, because the two compounds stimulate growth hormone through complementary pathways.
More direct long-term human research is still needed, but the underlying physiology is clear and compelling.
For researchers interested in growth hormone signaling, IGF-1, recovery, body composition, sleep, aging, and endocrine peptide biology, CJC-1295 No DAC remains an important compound to follow.
Research Areas / Search Keywords
CJC-1295 No DAC, CJC 1295 no DAC, Modified GRF 1-29, Mod GRF 1-29, GRF 1-29, growth hormone releasing hormone, GHRH, GHRH analogue, GHRH analog, growth hormone peptide, GH releasing peptide, pituitary peptide, growth hormone release, endogenous growth hormone, pulsatile growth hormone, GH pulse, GH secretion, IGF-1, IGF 1, growth hormone axis, GH IGF-1 axis, CJC ipamorelin, CJC-1295 ipamorelin, Modified GRF ipamorelin, ipamorelin combination, growth hormone secretagogue, ghrelin receptor, GHSR, pituitary signaling, body composition, fat metabolism, lipolysis, body fat research, muscle recovery, exercise recovery, tissue repair, connective tissue research, collagen turnover, sleep research, deep sleep, slow-wave sleep, nighttime growth hormone, recovery peptide, anti-aging research, aging research, somatopause, metabolic health, endocrine research, peptide research, experimental peptide, research peptide, CJC-1295 vs HGH, CJC-1295 DAC vs no DAC, Modified GRF vs CJC-1295.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Discussion of growth hormone, IGF-1, body composition, recovery, sleep, or endocrine research does not constitute medical advice or establish that CJC-1295 No DAC / Modified GRF 1-29 is safe or effective for human use. It is not FDA approved for the diagnosis, treatment, cure, or prevention of disease.